Sodium-Glucose Cotransporter 2 Inhibitor Use in Early-Phase Acute Coronary Syndrome with Severe Heart Failure.

Koshiro Kanaoka Yoshitaka Iwanaga Michikazu NakaiYuichi NishiokaTomoya MyojinShinichiro KuboKatsuki Okada Tatsuya Noda Yasushi Sakata Yoshihiro Miyamoto Yoshihiko Saito Tomoaki Imamura

Published in: European heart journal. Cardiovascular pharmacotherapy (2023)

SGLT2i use in patients with early-phase ACS showed a lower risk of primary outcome in patients with severe HF but the effect was not apparent in patients without severe HF.

Keyphrases

acute coronary syndrome
heart failure
early onset
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
left ventricular
magnetic resonance imaging
computed tomography
patient reported outcomes
atrial fibrillation
diffusion weighted imaging